(Ϯ)-Mecamylamine is a racemic mixture of a widely used brainpermeant noncompetitive inhibitor of muscle-type and neuronal nicotinic receptors (NNRs). The present studies evaluated whether the stereoisomers of this drug show different profiles for inhibition of the high-sensitivity (HS) and low-sensitivity (LS) isoforms of the human ␣4␤2 NNR subtype expressed in subclonal human epithelial 1 cells. We found that at low concentrations (micromolar range), TC-5214 [S-(ϩ)-mecamylamine] was more effective than TC-5213 [R-(Ϫ)-mecamylamine] in inhibiting the LS ␣4␤2 NNRs. In addition, we demonstrated that TC-5214 potentiated and TC-5213 inhibited agonist-induced activation of HS ␣4␤2 NNRs. The stereoselectivity of mecamylamine enantiomers at HS and LS ␣4␤2 receptors demonstrates that TC-5214 is the preferred stereoisomer for selective activation of HS, whereas it is more effective in suppressing LS receptor function. This feature could be relevant to therapeutic applications where such a selective mechanism of action is required.
In the last decade, more than 1000 articles have been published describing the use of mecamylamine as a pharmacological tool to confirm the involvement of nicotinic receptors in various physiological and pharmacological effects. Mecamylamine is a racemate of S-(ϩ)-and R-(Ϫ)-enantiomers. Just as endogenous amino acids and carbohydrates exist in predetermined distinct stereoisoforms (D-for carbohydrates and L-for amino acids) that are recognized differently as biological substrates, it is reasonable to expect that different stereoisomers of the same pharmacological compound may exert different actions on certain types of receptors. Only a few studies have addressed the differential effects of mecamylamine enantiomers on the function of nicotinic receptors (Newman et al., 2001; Papke et al., 2001) , and limited information is available regarding their effects on ␣4␤2 neuronal nicotinic receptor (NNR) function (Briggs et al., 2006a,b) . There are no published data on the selectivity of the enantiomers of mecamylamine for different stoichiometries of human ␣4␤2 NNRs.
The ␣4␤2 NNR represents the most abundant receptor subtype in the human brain and has begun to emerge as a relevant therapeutic target for several clinical indications. For example, an abnormal increase in cholinergic transmission has been linked to depression both in animal models and in human subjects (Shytle et al., 2002b) . This is consistent with findings that the classic NNR antagonist mecamylamine demonstrates antidepressant activity and that this activity is mediated by ␤2-containing NNRs (Rabenstein et al., 2006) . It is interesting that many antidepressants have shown noncompetitive antagonist-type activity at nicotinic receptors, which suggests an additional potential mechanism for their therapeutic actions in humans (Fryer and Lukas, 2008) . On the other hand, ␣4␤2 NNR agonists are procognitive, and this effect is blocked by high doses of mecamylamine (for review, see Levin and Simon, 1998) . Conversely, 10-fold lower doses of mecamylamine result in mnemonic effects (Terry et al., 1999) . This anomalous and unexpected activity has been reported in rodents and primates, but the mechanism responsible for this discordance has not yet been resolved. Compounding this complexity are recent observations that the gene products for the ␣4 and the ␤2 subunits that comprise the predominant mammalian brain NNR subtype can form heterogeneous targets (Whiting et al., 1987; Flores et al., 1992) . Human ␣4␤2 NNRs expressed in transfected cell lines and those expressed in vivo are present as a mixture of two stoichiometries, (␣4) 2 (␤2) 3 and (␣4) 3 (␤2) 2 , the former exhibiting high sensitivity (HS) and the latter low sensitivity (LS) to agonist activation. The calcium permeability and affinity for nicotine of these two stoichiometries were also shown to be different. The LS subtype showed lower affinity for nicotine and acetylcholine (EC 50 ϭ 10 and 50 M, respectively) and high permeability for calcium. In comparison, the HS subtype showed greater affinity for nicotine and acetylcholine (EC 50 ϭ 1 and 4 M, respectively) and lower calcium permeability (Buisson and Bertrand, 2001; Tapia et al., 2007) . Evidence for coexpression of the two isoforms in brain has been presented (Marks et al., 1999) . However, their specific roles in biological processes are presently unknown. Compounds with differential selectivity for the receptor isoforms have also been identified (Zwart and Vijverberg, 1998; Briggs et al., 2006b; Zwart et al., 2006) . The observation that the (␣4) 3 (␤2) 2 LS stoichiometry is more sensitive to the channel-blocking drugs mecamylamine and chlorisondamine suggests that its channel properties may differ from those of the (␣4) 2 (␤2) 3 HS isoform (Briggs et al., 2006a) . Therefore, the aim of the present investigations was to explore the mechanisms of action of both mecamylamine enantiomers on the HS and LS isoforms of human ␣4␤2 NNRs.
Materials and Methods
Subclonal Human Epithelial-h␣4␤2 Cells. Established techniques were used to introduce human ␣4 (S452) and ␤2 subunits (kindly provided by Dr. Ortrud Steinlein, Institute of Human Genetics, University Hospital, Ludwig-Maximilians-Universitä t, Munich, Germany) and subcloned into pcDNA3.1-zeocin and pcDNA3.1-hygromycin vectors, respectively, into native NNR-null SHEP1 cells to create the stably transfected, monoclonal subclonal human epithelial (SH-EP1)-h␣4␤2 cell line heterologously expressing human ␣4␤2 receptors. Cell cultures were maintained at low passage numbers (1-26 from frozen stocks to ensure the stable expression of the phenotype) in complete medium augmented with 0.5 mg/ml zeocin and 0.4 mg/ml hygromycin (to provide a positive selection of transfectants) and passaged once weekly by splitting the just-confluent cultures 1:20 to maintain cells in proliferative growth. Reverse transcriptase-polymerase chain reaction, immunofluorescence, radioligand-binding assays, and isotopic ion flux assays were conducted recurrently to confirm the stable expression of ␣4␤2 NNRs as message, protein, ligand-binding sites, and functional receptors.
Cell Handling. After removal from the incubator, the medium was aspirated, and cells were trypsinized for 3 min, washed thoroughly twice with recording medium, and resuspended in 2 ml of external solution (see below for composition). Cells were gently triturated to detach them from the plate and transferred into 4-ml test tubes from which cells were placed in the Dynaflow chip mount on the stage of an inverted Zeiss microscope (Carl Zeiss Inc., Thornwood, NY). On average, 5 min was necessary before the whole-cell recording configuration was established. To avoid modification of the cell conditions, a single cell was recorded per single load. To evoke short responses, agonists were applied using a Dynaflow system (Cellectricon, Inc., Gaithersburg, MD), where each channel delivered pressure-driven solutions at either 50 or 150 psi.
Electrophysiology. Conventional whole-cell current recordings, together with a computer-controlled Dynaflow system (Cellectricon, Inc.) for fast application and removal of agonists, were used in these studies. In brief, the cells were placed in a silicon chip bath mount on an inverted microscope (Carl Zeiss Inc.). Cells chosen for analysis were continuously perfused with standard external solution (60 l/ min). Glass microelectrodes (3) (4) (5) M⍀ resistance between the pipette and extracellular solutions) were used to form tight seals (Ͼ1 G⍀) on the cell surface until suction was applied to convert to conventional whole-cell recording. The cells were then voltage-clamped at holding potentials of Ϫ60 mV, and ion currents in response to application of ligands were measured. Whole-cell currents recorded with an Axon 700A amplifier were filtered at 1 kHz and sampled at 5 kHz by an ADC board 1440 (Molecular Devices) and stored on the hard disk of a PC computer. Whole-cell access resistance was less than 20 M⍀. Data acquisition of whole-cell currents was done using a Clampex 10 (Molecular Devices, Sunnyvale, CA), and the results were plotted using Prism 5.0 (GraphPad Software Inc., San Diego, CA). The experimental data are presented as the mean Ϯ S.E.M., and comparisons of different conditions were analyzed for statistical significance using Student's t tests. All experiments were performed at room temperature (22 Ϯ 1°C). Concentration-response profiles were fit to the Hill equation and analyzed using Prism 5.0. No differences in the fraction of responsive cells could be detected among experimental conditions. More than 90% of the cells responded to acetylcholine (ACh), and every cell presenting a measurable current was taken into account. Cells were held at Ϫ60 mV throughout the experiment. All drugs were prepared daily from stock solutions.
Neuronal ␣4␤2 receptor dose-response curves could be described by the sum of two empirical Hill equations comparable with methods described previously (Covernton and Connolly, 2000) : 
where y is the current (in picoamperes), A is the control maximum peak current (in picoamperes), is the time constant (in milliseconds), B is the current at equilibrium (in picoamperes), and t is the time (in milliseconds). Solutions and Drug Application. The standard external solution contained: 120 mM NaCl, 3 mM KCl, 2 mM MgCl 2 , 2 mM CaCl 2 , 25 mM D-glucose, and 10 mM HEPES and was adjusted to pH 7.4 with Tris base. In the experiments, ACh was applied as an agonist without atropine because our experimental data showed that 1 M atropine sulfate did not affect ACh-induced currents (not shown) and because atropine itself has been reported to block nicotinic receptors (Liu et al., 2008) . For all conventional whole-cell recordings, Trisϩ electrodes were used and filled with solution containing: 110 mM Tris phosphate dibasic, 28 mM Tris base, 11 mM EGTA, 2 mM MgCl 2 , 0.1 mM CaCl 2 , and 4 mM Mg-ATP, pH 7.3. To initiate whole-cell current responses, nicotinic agonists were delivered by moving cells from the control solution to agonist-containing solution and back so that solution exchange occurred within ϳ50 ms (based on 10 -90% peak current rise times). Intervals between drug applications (0.5-1 min) were adjusted specifically to ensure the stability of receptor responsiveness (without functional rundown), and the selection of pipette solutions used in most of the studies described here was made with the same objective. The drugs used in the present studies, including (Ϫ)-nicotine and ACh, were purchased from Sigma-Aldrich (St. Louis, MO).
Results
Human ␣4␤2 NNRs Display Biphasic Dose-Response Profiles. In this study, we used 13 concentrations of agonist to construct dose-response curves for ACh and nicotine. The results of these experiments are shown in Fig. 1 . We initially applied ACh (0.1-1000 M) and followed this with an application of nicotine (0.1-1000 M) and then one additional Under these experimental conditions, we were able to obtain full recovery of the initial responses to ACh after application of nicotine (Fig. 1A) . Logarithmic representations of the doseresponses are presented in Fig. 1B . Analysis of the peak current amplitude as a function of the ACh concentration revealed that dose-response curves were better fit using two Hill equations corresponding to the LS and HS components (F ϭ 15.96, p Ͻ 0.0001 for dual Hill equation versus single Hill equation). Best fits yielded HS coefficients of EC 50HS ϭ 4.1 Ϯ 0.3 M and n H 1 ϭ 0.8 Ϯ 0.05, whereas the LS values were EC 50LS ϭ 76 Ϯ 0.4 M and n H 2 ϭ 1.4 Ϯ 0.1 (n ϭ 5). The difference between the LS and HS EC 50 values was found to be statistically significant (Student's t test, p Ͻ 0.05, n ϭ 5). The Hill coefficients n H 1 and n H 2 were also found to be significantly different (Student's t test, p Ͻ 0.05, n ϭ 5), indicating different channel opening properties and/or selectivity for sodium and calcium ions (Buisson and Bertrand, 2001; Tapia et al., 2007) . The fractions of HS and LS components were 34 Ϯ 0.03 and 66 Ϯ 0.03% respectively. Figure 1C shows the biphasic fit and two monophasic theoretical curves, based on equations determined in Prism.
The biphasic nature of the dose-response profile was less marked for nicotine (Fig. 1, B and D) . However, analysis of the peak current amplitude as a function of the nicotine concentration revealed that dose-response curves were better fit using two Hill equations corresponding to LS and HS components (F ϭ 3.84, p Ͻ 0.027 for a dual Hill equation versus a single Hill equation). The calculated EC 50 values for the high-and low-sensitivity ␣4␤2 isoforms were EC 50HS ϭ 1.8 Ϯ 0.3 M and n H 1 ϭ 1.07 Ϯ 0.03, whereas the LS values were EC 50LS ϭ 15.8 Ϯ 0.4 M and n H 2 ϭ 1.82 Ϯ 0.19 (n ϭ 5). The difference between EC 50HS and EC 50LS values for nicotine was found to be significant (Student's t test, p Ͻ 0.05, n ϭ 5). In addition, the difference between n H 1 and n H 2 values was found to be significant (Student's t test, p Ͻ 0.05, n ϭ 5), indicating different channel opening properties and/or selectivity for sodium and calcium ions. The fractions of HS and LS components for nicotine were 43 Ϯ 0.03 and 57 Ϯ 0.03%, respectively. Figure 1D shows the biphasic fit and two . Plot C, biphasic dose-response to ACh control (E) fitted with dual Hill equation (parameters described in text). Two theoretical curves representing activation of HS (dotted line) and LS (solid line) were constructed with a single Hill equation using parameters taken from a dual fitting; ACh (exp) ϭ experimental data plus solid line two-site fit. Plot D, dose response for nicotine (Ⅺ) fitted with a dual Hill equation (symbols the same as in C). Two theoretical curves representing activation of HS (dotted line) and LS (solid line) were constructed with a single Hill equation using parameters taken from a dual fitting; Nic (exp) ϭ experimental data plus solid line two-site fit. E to G, typical traces of ACh-and nicotine-evoked currents are presented at the bottom (E, G, and F for ACh and nicotine, respectively). Horizontal bars, ACh and nicotine pulses at concentrations of 0.1, 1, 10, 100, and 1000 M (1000 M shown as thick line). Note that nicotine showed a faster rate of acute desensitization/open-channel block after current peak and a profound "hump" current at the end of application, known as open-channel block current. Unlike mecamylamine, profound open-channel blockade at high concentrations by nicotine was transient, and responses to consequent application of ACh showed a full recovery (shown in A).
Differential Pharmacologies of Mecamylamine Enantiomers 527
at ASPET Journals on July 9, 2017 jpet.aspetjournals.org monophasic theoretical curves, based on equations determined in Prism. These results are consistent with published studies (see Table 1 ) using a similar expression system (HEK293) and a fast (liquid filament) method of agonist application (Buisson and Bertrand, 2001 ). This suggests that the SH-EP1 cells used in this study fully express both the HS and LS types of ␣4␤2 NNRs. It should be mentioned that the dose-response curve parameters recorded in this study were based on electrophysiological measurements of current flow though the channels. Thus, the fractions of HS versus LS, the EC 50 s, and the Hill coefficients (n H 1 and n H 2) reported for nicotine and ACh are more directly related to the electrophysiological properties of channels such as open-channel characteristics, selectivity, and permeability for different cations (Tapia et al., 2007) , rather than for density of receptors on the cell surface or binding affinity. The separation between the EC 50 values for LS and HS components for nicotine (approximately 10-fold) suggests that the current obtained with low concentrations of nicotine (1-10 M) represents a mixture of responses of the HS and LS isoforms.
Selectivity of TC-5214 Inhibition of LS ␣4␤2 Receptors. To determine whether the HS and LS components display differences in their pharmacological profiles with respect to mecamylamine sensitivity, we conducted nicotine concentration-response studies in the absence or presence of either of the enantiomers, TC-5214 or TC-5213. Peak currents were measured and plotted versus concentration. The analysis indicated that the relationship between inhibition of peak current produced by 1 M TC-5214, and nicotine concentration was not linear (Fig. 2) . Responses induced by concentrations of nicotine up to 1 M (primarily reflecting HS activation) were not appreciably inhibited by TC-5214. In comparison, responses to concentrations of nicotine greater than 1 M (primarily reflecting LS activation) were profoundly inhibited (Fig. 2) . Increasing the concentration of TC-5214 to 2 M resulted in a more complete and nonselective inhibition of responses at all nicotine concentrations applied. These results suggest that at low concentrations, TC-5214 preferentially inhibits LS ␣4␤2 receptors. TC-5213 also inhibited responses to relatively high concentrations of nicotine (10 M), but this effect was not found to be statistically significant (data not shown, n ϭ 4).
Mecamylamine (racemate) has long been considered a nonselective, noncompetitive, open-channel blocker of nicotinic receptors. An important feature of mecamylamine-induced inhibition, particularly for the TC-5214 enantiomer, is a slow recovery/dissociation rate from nicotinic receptors (Papke et al., 2001) , which produces irreversible cumulative (use-dependent) block with repeated application. In this respect, an appropriate analysis of electrophysiological effects would involve a simple sequential kinetic model for open-channel block upon current decay. To investigate the selectivity of the Note that TC-5214 did not produce any noticeable block at low concentrations, whereas it significantly blocked responses to 2, 5, and 10 M nicotine (two-way ANOVA, p Ͻ 0.05, n ϭ 5). TC-5213 also produced some block of current; however, the effect was not statistically significant (data not shown). ‫,ء‬ significant differences.
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at ASPET Journals on July 9, 2017 jpet.aspetjournals.org mecamylamine enantiomers for the LS and HS ␣4␤2 isoforms, we used repeated applications of nicotine in the presence of TC-5214 or TC-5213 (Fig. 3) . In these experiments, we used 1 and 10 M concentrations of nicotine. To provide internal control for these experiments, we used the same cells throughout all experiments. First, 10 responses induced by 1 M nicotine were recorded as a control (until a stable baseline recording was achieved). This was followed by 10 responses to 1 M nicotine in the presence of 1 M TC-5214 or TC-5213. After this, we increased the concentration of nicotine to 10 M in the presence of TC-5214 or TC-5213. Both TC-5214 and TC-5213 induced a significant use-dependent decrease in response to 1 M nicotine compared with control responses. Neither enantiomer showed a significant difference in the extent of use-dependent inhibition (40 and 44% for TC-5213 and TC-5214, respectively, Fig. 3A) . However, the use-dependent inhibition of responses to 10 M nicotine by TC-5213 and TC-5214, obtained in the same experiments with the same cells, was significantly different. Thus, after 10 repetitive applications of 10 M nicotine, TC-5214 inhibited responses by 82% (significantly higher than the response with 1 M nicotine, two-way ANOVA, p Ͻ 0.05). In comparison, TC-5213 induced an inhibition of 10 M nicotine responses of 50% (not significantly different from results obtained with 1 M nicotine, 40%). It is important that there was a significant difference in the extent of usedependent inhibition between TC-5214 and TC-5213 responses to 10 M nicotine (two-way ANOVA, p Ͻ 0.05). These results suggest that use-dependent inhibition by TC-5214 was more selective for LS ␣4␤2 receptors compared with TC-5213. Because responses to 1 M nicotine probably represent a mixture of HS and LS ␣4␤2 receptors, and TC-5214 seemed to be more selective for LS ␣4␤2 receptors (compared with itself at 1 and 10 M nicotine and to TC-5213), it was unclear why there was an apparent absence of differences in experiments with 1 M nicotine for both enantiomers. To address this, we carried out a separate set of experiments where we repeated the experiments described above using only 10 M nicotine (Fig. 4) and the two mecamylamine enantiomers. The results of these experiments were consistent with the first set of experiments (inhibition of 80 and 55% with TC-5214 and TC-5213, respectively; see Fig. 4 ). We found that 10 applications of 10 M nicotine in the presence of TC-5214 were sufficient to produce nearly complete blockade of responses (Fig. 4) . In comparison, TC-5213 induced an approximately 60% inhibition. The IC 50 of TC-5214 was 1.5 pulses compared with 4.4 pulses for TC-5213. Thus, we confirmed that TC-5214 blocks LS receptors more efficiently than TC-5213. This suggests that TC-5214 is a more efficacious/fast open-channel blocker of LS ␣4␤2 receptors. These results corroborate the observations described above and suggest that TC-5214 is a more selective inhibitor of LS ␣4␤2 NNRs, consistent with data from the literature suggesting that TC-5214 should be a more efficacious inhibitor because of a slower dissociation rate from NNRs (Papke et al., 2001) .
One possible explanation for the absence of differences in use-dependent inhibition by TC-5214 and TC-5213 of 1 M nicotine responses is that TC-5214 simultaneously facilitates HS and inhibits LS ␣4␤2 receptors, resulting in compensa- Fig. 3 . Use-dependent block of responses to repetitive application of 1 and 10 M nicotine in the presence of TC-5214 and TC-5213. A, experimental design and results. After achieving a stable baseline with 1 M nicotine in controls (triangles, 5 min), 1 M nicotine (circles) was applied 10 times in the presence of TC-5213 (E) or TC-5214 (F). As a consequence, the same procedures were repeated with the same cells using 10 M nicotine (squares) and TC-5213 (Ⅺ) or TC-5214 (f). Both enantiomers blocked responses to nicotine in a use-dependent manner. TC-5213 and TC-5214 blocked responses to 1 M nicotine to the same extent (40 and 44%, respectively, n ϭ 4 cells). Blockade of responses to 10 M nicotine were profoundly different for TC-5214 and TC-5213 (82 and 50%, respectively, two-way ANOVA, p Ͻ 0.05, n ϭ 4). Note that there is no difference in blockade of 1 and 10 M nicotinic responses by TC-5213 (50 versus 40%) and a significant difference in blockade of 1 and 10 M nicotine responses by TC-5214 (44 versus 82%, two-way ANOVA, p Ͻ 0.05). ‫,ء‬ significant differences. B and C, representative first and 10th responses for TC-5213 and TC-5214 experiments corresponding to 1 (top) and 10 (bottom) M nicotine.
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at ASPET Journals on July 9, 2017 jpet.aspetjournals.org tory effects that mask intrinsic selectivities. To find out whether this was the case, we used low concentrations of TC-2559 (0.1-0.5 M), a compound known to be a fully selective agonist for HS ␣4␤2 NNRs . The results of these experiments are presented in Fig. 5 . We found that there was a small but significant facilitation of responses to TC-2559 in the presence TC-5214 (115%, twoway ANOVA, p Ͻ 0.05). In the same set of experiments, TC-5213 showed different effects on responses induced by TC-2559, inducing a slow steady-state decrease in response to 0.5 M TC-2559 (up to ϳ80% control). These results suggest that TC-5214 is a positive allosteric modulator of HS ␣4␤2 receptors, rather than an open-channel blocker. It is interesting that after application of a smaller concentration (0.1 M) of TC-2559 in the presence of TC-5214, the current amplitude doubled and remained relatively stable for 10 subsequent applications of TC-2559 (n ϭ 1; data not shown).
One final set of experiments was conducted to rule out the possibility that facilitation of responses to the HS ␣4␤2-selective agonist TC-2559 resulted from TC-5214 acting as an agonist at LS ␣4␤2 receptors and adding additional current to the TC-2559 signal. To address this, we conducted experiments with applications of either TC-5214 or TC-5213 alone to uncover potential agonist-like activity. We found that neither compound (0.1-1000 M) produced any measurable current (Fig. 6 , n ϭ 5 for each). Taken together, these results add further support to the conclusion that TC-5214 is a positive allosteric modulator of HS ␣4␤2 receptors, rather than a partial agonist at both the HS and LS ␣4␤2 isoforms.
Discussion
The two main findings of these studies are that 1) TC-5214 is a more efficacious antagonist of LS ␣4␤2 NNRs than either TC-5213 or racemic mecamylamine, and 2) TC-5214, unlike TC-5213 and much more than the racemate, potentiates agonist-induced activation of HS ␣4␤2 receptors. These data suggest that TC-5214 possesses complex stereoselectivity, i.e., TC-5214 is both a selective/efficacious blocker of LS ␣4␤2 NNRs and a positive allosteric modulator of HS ␣4␤2 NNRs. The latter property of S-(ϩ)-mecamylamine may explain the unexpected findings that racemic mecamylamine at low doses produces cognitive enhancement in animal models (Terry et al., 1999) , an effect typically attributed to nicotinic receptor agonists.
In the present studies, we confirmed the presence of HS and LS subforms of the ␣4␤2 NNR subtype in the SH-EP1 cell preparations. In previous studies, it had been reported that the slopes of concentration-response curves for ␣4␤2 NNR preparations were always close to unity, but results showed significant fluctuations in EC 50 values (Buisson et al., 1996; Shafaee et al., 1999) , suggesting the presence of additional sites. Determination of the human ␣4␤2 receptor activation concentration-response curve using a larger number of data points ultimately confirmed the initial hypothesis that more than one receptor subtype was present (Buisson and Bertrand, 2001) . There is now a solid body of evidence obtained from transiently and stably expressed ␣4␤2 NNRs in oocytes and in mammalian cell cultures confirming the coexistence of HS and LS ␣4␤2 receptor subtypes with distinct subunit stoichiometries. Conditions that enhance the expression of high-and low-sensitivity human ␣4␤2 receptor isoforms have also been published . The need to use biphasic Hill equations to describe ␣4␤2 dose-response curves is supported in recent years by a large body of published reports (Briggs et al., 2006a,b; Exley et al., 2006; Moroni et al., , 2008 Marks et al., 2007; Kuryatov et al., 2008) and is now the recommended approach (Bertrand and Bertrand, 2003) , which proposes that a biphasic fit to at least 12 data points should be the norm for concentration responses for ␣4␤2. Although different types of cells seem to express different ratios of HS and LS, the data conclusively indicate that the two sites are consistently coexpressed (see Table 1 ).
Functional NNRs are widely distributed in the brain, and numerous studies have shown that mecamylamine blocks nicotinic-induced mnemonic effects in normal and aged animals and in humans. Mecamylamine at higher doses produces cognitive impairment in healthy young adults (20 mg) and in the elderly (10 mg). The latter may be because of a greater susceptibility with age, possibly linked to an agerelated decrease in cholinergic tone. Our observations suggest that TC-5214, by enhancing ␣4␤2 functionality, may be less likely to induce amnesic effects with escalating doses. At low doses of TC-5214, similar to those used in clinical practice for mecamylamine, procognitive effects may be expected, based on facilitation of ␣4␤2 NNR targets implicated in cognitive function.
Mecamylamine is widely used as a pharmacological tool to confirm the involvement of nicotinic receptors in the observed biological effects. Mecamylamine inhibits the release of neurotransmitters resulting from NNR activation and lowers the basal firing rate of dopaminergic neurons projecting to the striatum (Shytle et al., 2002b) . The major norepinephrine (NE)-producing neurons comprising the locus coeruleus abundantly express NNRs and receive massive cholinergic inputs from various central nervous system areas, such as the pontine reticular formation. The secretion of NE from synaptic terminals of these neurons is stimulated by activation of NNRs. Mecamylamine has been shown to reduce plasma NE levels in humans and in the hippocampus to block NE release mediated by both NNRs and N-methyl-D-aspartate receptors (Shytle et al., 2002b) . Based on our data, it is expected that TC-5214 would have similar or enhanced effects on inhibition of various NNRs. However, in contrast to TC-5213, low doses of TC-5214 should facilitate ␣4␤2 functionality and show enhanced efficacy compared with mecamylamine racemate. Therefore, in considering the doses of mecamylamine that inhibit cholinergic function, one should take into account the opposite effects of both enantiomers on HS ␣4␤2 NNRs seen at low doses and the resultant effects on physiological functions to properly interpret the results. Dissection of these pathways will benefit from the separate use of TC-5214 and TC-5213 to unravel the role of HS ␣4␤2 NNRs in the overall response.
More extensive blockade of ␣4␤2 NNRs by TC-5214 compared with its R-(Ϫ)-enantiomer has been observed previously (Papke et al., 2001 ). This effect was attributed to a slower dissociation rate of TC-5214 from the receptors, possibly because of selective trapping of TC-5214 within the receptor pore. Our results confirm and extend these findings, providing evidence for the selectivity of TC-5214 between HS and LS ␣4␤2 receptor isoforms. The finding that racemic mecamylamine is more selective in blocking LS versus HS ␣4␤2 receptors was previously published (Briggs et al., 2006a) . Our results suggest that the S-(؉)-enantiomer TC-5214 is primarily responsible for this selectivity. It was unexpected that TC-5214 positively modulates agonist-induced activation of HS ␣4␤2 receptors.
The increased selectivity (LS versus HS) and efficacy (more efficacious block of LS) of TC-5214 may have important implications for clinical trials in several indications. For example, dementia and major depression represent two of the most significant unmet medical needs today. The involvement of cholinergic systems in the symptomatology of these indications is well established. The classic nicotinic cholinergic antagonist (Ϯ)-mecamylamine was approved by the United States Food and Drug Administration nearly 50 years ago (as Inversine) to treat hypertension, based on its well documented action as a noncompetitive antagonist of ganglionic nicotinic receptors in the peripheral nervous system (Moyer et al., 1955; Freis and Wilson, 1956) . Interest in this drug has been rejuvenated more recently by a growing body of evidence from both animal and human studies suggesting that smaller doses of mecamylamine can improve cognition and/or elicit antidepressant-like effects (Levin et al., 1987; Terry et al., 1999; Laje et al., 2001; Rezvani et al., 2002; Shytle et al., 2002a,b; Pocivavsek et al., 2006; Rabenstein et al., 2006) . It has been suggested that the antidepressant-like effects seen in animals and humans are mediated through a reduction of hypercholinergic tone associated with depressed states (Janowsky et al., 1972; Shytle et al., 2002c; Janowsky, 2005) . However, the basis for cognitive enhancement seen with low doses of mecamylamine remains unclear. Moreover, the procognitive effects of mecamylamine represent a paradox because a gain in cognitive function is typically attributed to the action of NNR agonists . 
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There is a growing body of evidence that both activation and desensitization of NNRs may contribute to the beneficial behavioral effects of nicotine (Picciotto et al., 2008) . In this regard, administration of antagonists may produce effects similar to those that result from NNR desensitization. The data obtained in the present studies did not address this possibility. In this article, we report previously unknown actions of TC-5214, the S-(ϩ)-enantiomer of mecamylamine involving subtypes of ␣4␤2 NNRs that are known to mediate the procognitive effects of nicotinic agonists. TC-5214 specifically demonstrates dual agonist/antagonist pharmacology at the high-and low-sensitivity ␣4␤2 NNR isoforms described previously (Flores et al., 1992; Zwart and Vijverberg, 1998; Marks et al., 1999; Zwart et al., 2006; Tapia et al., 2007) , whereby it activates the high-sensitivity subclass of ␣4␤2 NNRs and inhibits the low-sensitivity subclass of ␣4␤2 NNRs. These findings suggest that the differential stereoselectivity of TC-5214 for the high-and lowsensitivity ␣4␤2 NNR subclasses may underlie the paradoxical cognitive enhancing effects seen in studies using low doses of mecamylamine (Terry et al., 1999; Kholdebarin et al., 2007) and that TC-5214 may also be the preferred enantiomer responsible for the reported antidepressant effects of racemic (Ϯ)-mecamylamine (Rabenstein et al., 2006) . These findings have direct relevance to the use of TC-5214 in evaluating the role of drugs targeting cholinergic pathways both in dementia and major depression.
